Last reviewed · How we verify

Lenvima (LENVATINIB)

Eisai · FDA-approved approved Small molecule Verified Quality 75/100

Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells.

Lenvima (Lenvatinib) is a small molecule kinase inhibitor developed by Eisai Inc, targeting the proto-oncogene tyrosine-protein kinase receptor Ret. It is a FDA-approved treatment for various cancers, including endometrial carcinoma, follicular thyroid carcinoma, and renal cell carcinoma. Lenvima works by inhibiting the growth of cancer cells and reducing tumor size. As of now, it remains a patented product with no generic manufacturers. Key safety considerations include potential liver damage and hypertension.

At a glance

Generic nameLENVATINIB
SponsorEisai
Drug classKinase Inhibitor [EPC]
TargetProto-oncogene tyrosine-protein kinase receptor Ret
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved
First approval2015
Annual revenue1053

Mechanism of action

Lenvatinib is kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet derived growth factor receptor alpha (PDGFR), KIT, and RET. Lenvatinib also exhibited antiproliferative activity in hepatocellular carcinoma cell lines dependent on activated FGFR signaling with concurrent inhibition of FGF-receptor substrate (FRS2) phosphorylation. In syngeneic mouse tumor models, lenvatinib decreased tumor-associated macrophages, increased activated cytotoxic cells, and demonstrated greater antitumor activity in combination with an anti-PD-1 monoclonal antibody compared to either treatment alone.The combination of lenvatinib an

Approved indications

Common side effects

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: